Nelson Vergel
Founder, ExcelMale.com
The gluten free diet (no wheat, barley, rye) is the only treatment for celiac disease. But many companies and researchers are investigating and doing clinical trials for different treatments for people diagnosed with celiac disease. In the last few days Joseph Murray, M.D. from the Division of Gastroenterology and Hepatology at the Mayo Clinic offered an update on the testing of larazotide acetate. Murray is quoted in Gastroenterology and Endoscopy News‘ report that the latest clinical trial findings showed “significant symptom reduction in celiac disease”.
http://www.thesavvyceliac.com/2014/09/23/promising-news-treatment-for-celiac-disease/
Larazotide acetate will be the first. Developed by Alba Therapeutics, founded by internationally renowned coeliac voice Dr Alessio Fasano - author of the brilliant Gluten Freedom - it works by making the gut less 'leaky' to gluten peptide molecules. It is not expected to allow deviation from a gluten-free diet, but to act as a complement to it - to help prevent the effects of accidental cross-contamination when eating out, or offering protection against the low-level gluten ingestion coeliacs almost invariably live with.
The second is latiglutenase - ALV003 by Alvine Pharmaceuticals - an enzyme rather than a drug, per se, and one devised to break down gluten proteins into harmless fractions in the small intestine. Research has shown that enzymes are the preferred form of treatment for coeliacs.
The two could, potentially, act complementarily.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791048/
http://www.thesavvyceliac.com/2014/09/23/promising-news-treatment-for-celiac-disease/
Larazotide acetate will be the first. Developed by Alba Therapeutics, founded by internationally renowned coeliac voice Dr Alessio Fasano - author of the brilliant Gluten Freedom - it works by making the gut less 'leaky' to gluten peptide molecules. It is not expected to allow deviation from a gluten-free diet, but to act as a complement to it - to help prevent the effects of accidental cross-contamination when eating out, or offering protection against the low-level gluten ingestion coeliacs almost invariably live with.
The second is latiglutenase - ALV003 by Alvine Pharmaceuticals - an enzyme rather than a drug, per se, and one devised to break down gluten proteins into harmless fractions in the small intestine. Research has shown that enzymes are the preferred form of treatment for coeliacs.
The two could, potentially, act complementarily.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791048/